CA2002182A1 - Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use - Google Patents

Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use

Info

Publication number
CA2002182A1
CA2002182A1 CA 2002182 CA2002182A CA2002182A1 CA 2002182 A1 CA2002182 A1 CA 2002182A1 CA 2002182 CA2002182 CA 2002182 CA 2002182 A CA2002182 A CA 2002182A CA 2002182 A1 CA2002182 A1 CA 2002182A1
Authority
CA
Canada
Prior art keywords
methods
compositions
premenstrual
treating
luteal phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2002182
Other languages
French (fr)
Other versions
CA2002182C (en
Inventor
Richard J. Wurtman
Judith J. Wurtman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Priority to CA 2002182 priority Critical patent/CA2002182C/en
Publication of CA2002182A1 publication Critical patent/CA2002182A1/en
Application granted granted Critical
Publication of CA2002182C publication Critical patent/CA2002182C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions useful in the treatment of disturbances of appetite, disturbances of mood, or both, associated with premenstrual syndrome; as well as methods of use therefor. The compositions include serotoninergic drugs, such as d-fenfluramine and fluoxetine.
CA 2002182 1989-11-03 1989-11-03 Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use Expired - Fee Related CA2002182C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2002182 CA2002182C (en) 1989-11-03 1989-11-03 Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2002182 CA2002182C (en) 1989-11-03 1989-11-03 Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use

Publications (2)

Publication Number Publication Date
CA2002182A1 true CA2002182A1 (en) 1991-05-03
CA2002182C CA2002182C (en) 2000-06-13

Family

ID=4143458

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2002182 Expired - Fee Related CA2002182C (en) 1989-11-03 1989-11-03 Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use

Country Status (1)

Country Link
CA (1) CA2002182C (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108591A1 (en) 2005-04-11 2006-10-19 Novartis Ag 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands
EP2336129A1 (en) 2004-06-18 2011-06-22 Novartis AG 1-aza-bicyclo[3.3.1]nonanes
EP2354141A1 (en) 2005-12-16 2011-08-10 Novartis AG (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1h-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders.
EP2361914A1 (en) 2005-12-16 2011-08-31 Novartis AG [(1h-indol-5-yl)-heteroaryloxy]-(1-aza-bicyclo[3.3.1]nonanes as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders.
EP2457911A1 (en) 2004-07-14 2012-05-30 Novartis AG 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nAChR ligands for the treatment of CNS diseases.

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
CA3139771A1 (en) * 2019-05-31 2020-12-03 Susan Florence Evans Methods, compositions and devices for treating neuroinflammatory conditions

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336129A1 (en) 2004-06-18 2011-06-22 Novartis AG 1-aza-bicyclo[3.3.1]nonanes
EP2457911A1 (en) 2004-07-14 2012-05-30 Novartis AG 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nAChR ligands for the treatment of CNS diseases.
WO2006108591A1 (en) 2005-04-11 2006-10-19 Novartis Ag 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands
EP2463278A1 (en) 2005-04-11 2012-06-13 Novartis AG 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands
EP2468732A1 (en) 2005-04-11 2012-06-27 Novartis AG 1H-Quinazoline-2,4-diones
EP2476671A1 (en) 2005-04-11 2012-07-18 Novartis AG 1H-Quinazoline-2,4-diones
EP2354141A1 (en) 2005-12-16 2011-08-10 Novartis AG (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1h-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders.
EP2361914A1 (en) 2005-12-16 2011-08-31 Novartis AG [(1h-indol-5-yl)-heteroaryloxy]-(1-aza-bicyclo[3.3.1]nonanes as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders.

Also Published As

Publication number Publication date
CA2002182C (en) 2000-06-13

Similar Documents

Publication Publication Date Title
CA2001572A1 (en) Compositions for treating tobacco withdrawal symptoms
EP0419653A4 (en) Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
DE69202207D1 (en) Process for the preparation of 1-chloro-1,1,3,3,3-pentafluoropropane and 1,1,1,3,3,3-hexafluoropropane.
CA2083179A1 (en) Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
AU610036B2 (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis inflammation and as immunosuppressants
IL96458A0 (en) Isoxazolines,their preparation,and their use as plantprotecting agents
EP0391774B1 (en) Process for the synthesis of type silicoaluminophosphate molecular sieve precursors, precursors therefrom and their application in the preparation of these molecular sieves.
AU5642294A (en) Bacteriocidal gas composition and process for preparing the same
ZA899725B (en) N-aryl-azetidinones,their preparation process and their use as elastage inhibitors
DE3856295D1 (en) TREATMENT OF PREMIUM OR LATE LUTEAL PHASE SYNDROME
HUT47103A (en) Process for producing 1,4-benzoxazine derivatives and pharmaceutical compositions comprising the same
AU7239794A (en) Process for preparing 5,8-dihydronaphthoquinone derivatives, novel 5,8-dihydronaphthoquinone derivatives and their use as anticancer agent
LTIP1720A (en) Novel antiarrhythmic agents, process for the preparation and use thereof
CA2002182A1 (en) Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use
EP0377274A3 (en) Adamantane derivatives, process for their preparation, compositions containing them and their use as organoleptics and deodorants
PT66089A (en) Process for preparing 1,2-benzisothiazolin-3-ona with anti-thrombotic effect,application of same for the preparation of pharmaceutical compositions with anti-thrombic effect and application of these pharmaceutical compositions for the treatment of thrombosis
ZA925892B (en) Organic nitrates, processes for their preparation and their use in the treatment of cardiovascular diseases.
EP0318233A3 (en) Improvements in or relating to serotonin and norepinephrine uptake inhibitors
IL93339A0 (en) 2,3,23-trihydroxy-urs-12-ene and its derivatives,processes for their preparation and their use
GB2235198B (en) Novel aminopropanol derivatives,process for their preparation and pharmaceutical compositions comprising the same
ZA898775B (en) Cyclopropyl-substituted azolylmethylcarbinols,processes for their preparation and their use as medicaments
IL95210A0 (en) 14,17alpha-etheno-and-ethanoestratrienes,process for the preparation thereof and pharmaceutical compositions containing the same
CA2019745A1 (en) Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
EP0386920A3 (en) 2-hydroxy-3-thienyloxypropylamino derivatives
HUT53773A (en) Antidotums containing substituted 1,8-naphtiridine derivatives as aktive components and process for producing the active components

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed